Thomas Englese
Directeur/Membre du Conseil chez Therakos (UK) Ltd.
Postes actifs de Thomas Englese
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Therakos (UK) Ltd.
 Therakos (UK) Ltd. Medical/Nursing ServicesHealth Services Founded in 2012, Therakos (UK) Ltd. is a subsidiary of Mallinckrodt Plc. The company is based in Staines-upon-Thames, UK. The British company develops immune cell therapies that are delivered through extracorporeal photopheresis. | Directeur/Membre du Conseil | 30/10/2015 | - |
Historique de carrière de Thomas Englese
Anciens postes connus de Thomas Englese
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| MALLINCKRODT PLC | Corporate Officer/Principal | 01/04/2015 | 01/07/2019 |
| IKARIA, INC. | Corporate Officer/Principal | 01/10/2008 | 01/03/2015 |
| BAXTER INTERNATIONAL INC. | Corporate Officer/Principal | 01/01/2002 | 01/01/2008 |
| ELUTIA INC. | Corporate Officer/Principal | 01/07/2019 | - |
Formation de Thomas Englese
| The Pennsylvania State University | Masters Business Admin |
| Villanova University | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 6 |
| Royaume-Uni | 2 |
| Irlande | 2 |
Opérationnelle
| Corporate Officer/Principal | 4 |
| Director/Board Member | 1 |
| Masters Business Admin | 1 |
Sectorielle
| Health Technology | 5 |
| Consumer Services | 3 |
| Health Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| ELUTIA INC. | Health Technology |
| MALLINCKRODT PLC | Health Technology |
| BAXTER INTERNATIONAL INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Therakos (UK) Ltd.
Therakos (UK) Ltd. Medical/Nursing ServicesHealth Services Founded in 2012, Therakos (UK) Ltd. is a subsidiary of Mallinckrodt Plc. The company is based in Staines-upon-Thames, UK. The British company develops immune cell therapies that are delivered through extracorporeal photopheresis. | Health Services |
Ikaria, Inc.
 Ikaria, Inc. BiotechnologyHealth Technology Ikaria, Inc. operates as a biotherapeutics company focused on developing and commercializing innovative therapeutics and interventions designed to meet the medical needs of critically ill patients. It offers INOMAX for inhalation, which is used to treat newborns suffering from hypoxic respiratory failure, and is making a major impact on the critical care environment. The company was founded on August 18, 2006 and is headquartered in Clinton, NJ. | Health Technology |
- Bourse
- Insiders
- Thomas Englese
- Expérience
